Is clinical trial data showing positive progress for the treatment of eosinophilic esophagitis?

References

• Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158(6):1776086.
   Google Scholar
• Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22.
   PubMed Web of Science ®Google Scholar
• Murali AR, Gupta A, Attar BM, et al. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled trials. J Gastroenterol Hepatol. 2016;31(6):1111–1119.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335–358.
   PubMed Web of Science ®Google Scholar
• Ma C, Schoepfer AM, Dellon ES, et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2022;149(2):659–670.
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomized, placebo-controlled, double-blind trial. Gut. 2010;59(1):21–30.
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–463.
   PubMed Web of Science ®Google Scholar
• Hirano I, Collins MH, Assouline-Dayan Y, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. 2019;156(3):592–603.
   PubMed Web of Science ®Google Scholar
• Ma C, van Rhijn BD, Jairath V, et al. Heterogeneity in clinical, endoscopic, and histologic outcome measures and placebo response rates in clinical trial of eosinophilic esophagitis: a systematic review. Clin Gastroenterol Hepatol. 2018;16(11):1714–1729.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration Center for Drug Evaluation and Research (CDER). September 2020. Eosinophilic esophagitis: development drugs for treatment. Guidance for Industry. (online at: fda.gov/ regulatory-information/search-fda-guidance-documents/eosinophilic-esophagitis-developing-drugs-treatment-guidance-industry) cited 2022 Oct 09
   Google Scholar
• Hirano I, Collins MH, Katzka DA, et al. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial. Clin Gastroenterol Hepatol. 2022;20(3):525–534.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Collins MH, Katzka DA, et al. Long-term treatment of eosinophilic esophagitis with budesonide oral suspension. Clin Gastroenterol Hepatol. 2022;20(7): 1488–1498.
   PubMedGoogle Scholar
• Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74–86.
   PubMed Web of Science ®Google Scholar
• Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159(5):1672–1685.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Lucendo AJ, Schlag C, et al. Fluticasone propionate orally disintegrating tablet (APT-1011) for eosinophilic esophagitis: randomized controlled trial. Clin Gastroenterol Hepatol. 2022;in press. DOI:10.1016/j.cgh.2022.02.013.
   Google Scholar
• Dellon E, Rothenberg M, Hirano I, et al. Dupilumab improves health-related quality of life (HRQoL) and reduces symptom burden in patients with eosinophilic esophagitis (EoE): results from part A of a randomized, placebo-controlled three-part phase 3 study. J Allergy Clin Immunol. 2021;147(2):AB91.
   Web of Science ®Google Scholar
• Rothenberg M, Dellon ES, Bredenoord A, et al. Dupilumab improves clinical and histologic aspects of disease in adult and adolescent patient with eosinophilic esophagitis at week 24: results from part B of the 3-part LIBERTY EoE TREET study. J Allergy Clin Immunol. 2022;149(2):AB312.
   Web of Science ®Google Scholar
• Dellon ES, Rothenberg ME, Collins, MH. Dupilumab efficacy and safety up to 52 weeks in adult and adolescent patients with eosinophilic esophagitis: results from part A and C of a randomized, placebo-controlled, three-part, phase 3 liberty EOE treet study. Presented at UEG Week Virtual. 2021;2021 Oct 3-5.
   Google Scholar
• Kuang FL, De Melo MS, Makiya M, et al. Benralizumab completely depletes gastrointestinal tissue eosinophils and improves symptoms in eosinophilic gastrointestinal disease. J Allergy Clin Immunol Pract. 2022;10(6):1598–1605.e2. in press.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Peterson KA, Murray JA, et al. Anti-siglec-8 antibody for eosinophilic gastritis and duodenitis. N Engl J Med. 2020;383(17):1624–1634.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Collins MH, Rothenberg ME, et al. Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2021;19(3):473–483.
   PubMed Web of Science ®Google Scholar